Aims: To compare the safety and efficacy of ormeloxifene and norethisterone in treatment of dysfunctional uterine bleeding as measured by decrease in menstrual blood loss using pictorial blood assessment chart. To assess the percentage change in haemoglobin and endometrial thickness before and after treatment. To assess the subjective improvement in life style as evaluated by a five point Likert scale. Methods: A double blinded randomized control trial was conducted on patients attending gynaecology OPD with complaints of menorrhagia with following inclusion criteria women between 18 and 51 years of age, absence of coagulopathies and any pelvic pathology, not taking any drug affecting menstruation, no hormonal therapy in previous three months and normal renal function. Findings and Interpretation: The menstrual blood loss was observed to decrease by 19.31% at end of two months, 30.74% at the end of four months and 43.25% at end of six months in case of norethisterone and 20.72% at the end of two months, 43.37% at end of four months and 59.50% at the end of six months in case of Ormeloxifene. There was an increase in haemoglobin percentage in both the groups and it was significantly better in case of Ormeloxifene. PBAC score and endometrial thickness improvement was better in case of ormeloxifene compared to norethisterone. The side effects were similar in both the cases except for follicular cyst which was seen in Ormeloxifene group. I. Introduction A woman can expect roughly 400 menstrual cycles during her reproductive lifespan, and it is estimated that up to 20% of women will have excessive menstrual blood loss. Although age of menopause has remained the same over this century, the magnitude of menstrual disorders has increased, likely because of shortened breast-feeding intervals, fewer pregnancies per woman, higher frequency of permanent sterilization, and later age of conception. Dysfunctional uterine bleeding is a diagnosis of exclusion when organic, systemic and pelvic pathology all have been ruled out. Once a diagnosis has been reached with the aid of history, examination, haematological and endocrine investigations, and dilatation and curettage when appropriate, medical treatment is the usual first line approach. The treatment options for dysfunctional uterine bleeding are diverse, which can be finally tailored to cater the needs of patients of different socioeconomic background, different age groups and different reproductive needs. Treatment options range from offering medical measures such as cyclooxygenase inhibitors, tranexamic acid, hormonal agents and in cases not managed by medical therapy offering surgical management. Trials comparing the various modalities have flooded the literature but ambiguity still exists. Norethisterone is still the most frequently prescribed drug for dysfunctional uterine bleeding serving 38% of the patient population the reason being cost effectiveness and absence of side effects. Ormeloxifene (also known as centchroman) is one of the selective estrogen receptor modulators used primarily as a contraceptive, but it is also effective in dysfunctional uterine bleeding. We undertook the study to compare the safety and efficacy of the two drugs in dysfunctional uterine bleeding.